Literature DB >> 12599086

Tracking the source of the hepatitis B virus-specific CD8 T cells during lamivudine treatment.

Fabio Malacarne1, George J M Webster, Stephanie Reignat, Jim Gotto, Shahriar Behboudi, Andrew K Burroughs, Geoffrey M Dusheiko, Roger Williams, Antonio Bertoletti.   

Abstract

Lamivudine treatment in chronic hepatitis B leads to the reconstitution of virus-specific T cells in the circulation, but it is not clear whether this is the preferential result of T cell efflux from the liver or lymph nodes. To address this question, the frequency and function of liver-, lymph node-, and blood-derived hepatitis B virus (HBV)-specific CD8 T cells were analyzed in patients treated with lamivudine and undergoing liver transplantation. HBV-specific CD8 T cells, identified in portal lymph nodes, were able to expand in vitro after antigen-specific stimulation and displayed a heterogeneous profile of cytokine production. These findings suggest that the peripherally reconstituted HBV-specific CD8 T cells can originate from precursor cells within lymph nodes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12599086     DOI: 10.1086/368369

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection.

Authors:  Ornella Franzese; Patrick T F Kennedy; Adam J Gehring; Jim Gotto; Roger Williams; Mala K Maini; Antonio Bertoletti
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

2.  Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy.

Authors:  J Judy Chang; Fiona Wightman; Angeline Bartholomeusz; Anna Ayres; Stephen J Kent; Joseph Sasadeusz; Sharon R Lewin
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

3.  Differential tissue-specific regulation of antiviral CD8+ T-cell immune responses during chronic viral infection.

Authors:  Shenghua Zhou; Rong Ou; Lei Huang; Graeme E Price; Demetrius Moskophidis
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

Review 4.  Therapeutic vaccination for treatment of chronic hepatitis B.

Authors:  Tamsin Cargill; Eleanor Barnes
Journal:  Clin Exp Immunol       Date:  2021-06-08       Impact factor: 5.732

5.  Characterization of Antigen-Presenting Cell Subsets in Human Liver-Draining Lymph Nodes.

Authors:  Patrick P C Boor; Brenda M Bosma; Khe T C Tran; Luc J W van der Laan; Hanneke Hagenaars; Jan N M IJzermans; Herold J Metselaar; Jaap Kwekkeboom
Journal:  Front Immunol       Date:  2019-03-14       Impact factor: 7.561

Review 6.  Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact.

Authors:  Sifan Zhang; Becca Asquith; Richard Szydlo; John S Tregoning; Katrina M Pollock
Journal:  Immunother Adv       Date:  2021-07-02

7.  Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy.

Authors:  George J M Webster; Stephanie Reignat; David Brown; Graham S Ogg; Louise Jones; Suranjith L Seneviratne; Roger Williams; Geoffrey Dusheiko; Antonio Bertoletti
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

8.  Hepatitis B virus (HBV)-specific T-cell responses to recombinant HBV core protein in patients with normal liver function and co-infected with chronic HBV and human immunodeficiency virus 1 (HIV-1).

Authors:  Xin Zhang; Hanqian Xing; Xia Feng; Haiping Zhang; Yi Wang; Huiping Yan
Journal:  Virol J       Date:  2013-07-12       Impact factor: 4.099

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.